Event Type
Disclosure
Voluntary
Variant
8-K
Other Events. On January 6, 2026, Processa Pharmaceuticals, Inc. (the “Company”) received written notification from the NASDAQ Stock Market Listing Qualificatio
Financial Statements and Exhibits (d) Exhibits Exhibit Description 104 Cover Page Interactive Data File (formatted as Inline XBRL) SIGNATURE Pursuant to the req